{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:15:09Z","timestamp":1782738909710,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11845-023-03356-z","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T14:04:34Z","timestamp":1682431474000},"page":"2663-2671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiotherapy after radical prostatectomy for prostate cancer: clinical outcomes and factors influencing biochemical recurrence"],"prefix":"10.1007","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7863-8459","authenticated-orcid":false,"given":"Ichiro","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"3356_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2011.10.010","volume":"61","author":"AJ Stephenson","year":"2012","unstructured":"Stephenson AJ, Bolla M, Briganti A et al (2012) Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 61:443\u2013451","journal-title":"Eur Urol"},{"key":"3356_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ijrobp.2004.06.018","volume":"61","author":"C Vargas","year":"2005","unstructured":"Vargas C, Kestin LL, Weed DW et al (2005) Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61:714\u2013724","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR3","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181:956\u2013962","journal-title":"J Urol"},{"key":"3356_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, Van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911). Lancet 380:2018\u20132027","journal-title":"Lancet"},{"key":"3356_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial. Eur Urol 66:243\u2013250","journal-title":"Eur Urol"},{"key":"3356_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.eururo.2013.11.045","volume":"66","author":"A Briganti","year":"2014","unstructured":"Briganti A, Karnes RJ, Joniau S et al (2014) Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 66:479\u2013486","journal-title":"Eur Urol"},{"key":"3356_CR7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","volume":"65","author":"D Pfister","year":"2014","unstructured":"Pfister D, Bolla M, Briganti A et al (2014) Early salvage radiotherapy following radical prostatectomy. Eur Urol 65:1034\u20131043","journal-title":"Eur Urol"},{"key":"3356_CR8","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","volume":"34","author":"BJ Stish","year":"2016","unstructured":"Stish BJ, Pisansky TM, Harmsen WS et al (2016) Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 34:3864\u20133871","journal-title":"J Clin Oncol"},{"key":"3356_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","volume":"197","author":"A Abugharib","year":"2017","unstructured":"Abugharib A, Jackson WC, Tumati V et al (2017) Exceedingly early salvage radiotherapy improves distant metastasis-free survival. J Urol 197:662\u2013668","journal-title":"J Urol"},{"key":"3356_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial. Lancet 396:1413\u20131421","journal-title":"Lancet"},{"key":"3356_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21:1331\u20131340","journal-title":"Lancet Oncol"},{"key":"3356_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU-17): A randomised, phase 3 trial. Lancet Oncol 21:1341\u20131352","journal-title":"Lancet Oncol"},{"key":"3356_CR13","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A et al (2020) Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data. Lancet 396:1422\u20131431","journal-title":"Lancet"},{"key":"3356_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ijrobp.2020.12.022","volume":"109","author":"RC Chen","year":"2021","unstructured":"Chen RC, Choudhury A (2021) Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for Men with Adverse Pathologic Features-The Debate Continues. Int J Radiat Oncol Biol Phys 109:839\u2013843","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100753","volume":"6","author":"N Shimoyachi","year":"2021","unstructured":"Shimoyachi N, Yoshioka Y, Sasamura K et al (2021) Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy. Adv Radiat Oncol 6:100753","journal-title":"Adv Radiat Oncol"},{"key":"3356_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.eururo.2012.04.056","volume":"62","author":"A Briganti","year":"2012","unstructured":"Briganti A, Wiegel T, Joniau S et al (2012) Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. Eur Urol 62:472\u2013487","journal-title":"Eur Urol"},{"key":"3356_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jama.291.11.1325","volume":"291","author":"AJ Stephenson","year":"2004","unstructured":"Stephenson AJ, Shariat SF, Zelefsky MJ et al (2004) Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy. JAMA 291:1325\u20131332","journal-title":"JAMA"},{"key":"3356_CR18","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035\u20132041","journal-title":"J Clin Oncol"},{"key":"3356_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.eururo.2015.10.009","volume":"69","author":"N Fossati","year":"2016","unstructured":"Fossati N, Karnes RJ, Cozzarini C et al (2016) Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69:728\u2013733","journal-title":"Eur Urol"},{"key":"3356_CR20","first-page":"19","volume":"19","author":"B Spieler","year":"2017","unstructured":"Spieler B, Goldstein J, Lawrence YR et al (2017) Salvage Radiation Therapy for Biochemical Failure Following Radical Prostatectomy. Isr Med Assoc J 19:19\u201324","journal-title":"Isr Med Assoc J"},{"key":"3356_CR21","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1002\/cncr.28222","volume":"119","author":"NC Sheets","year":"2013","unstructured":"Sheets NC, Hendrix LH, Allen IM et al (2013) Trends in the use of postprostatectomy therapies for patients with prostate cancer: A surveillance, epidemiology, and end results Medicare analysis. Cancer 119:3295\u20133301","journal-title":"Cancer"},{"key":"3356_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2015.03.122","volume":"194","author":"MJ Maurice","year":"2015","unstructured":"Maurice MJ, Zhu H, Abouassaly R (2015) Low use of immediate and delayed postoperative radiation for prostate cancer with adverse pathological features. J Urol 194:972\u2013976","journal-title":"J Urol"},{"key":"3356_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA et al (2005) Risk of prostate cancer-specific mortality following radical prostatectomy. JAMA 294:433\u2013439","journal-title":"JAMA"},{"key":"3356_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eururo.2013.08.022","volume":"66","author":"MC Mir","year":"2014","unstructured":"Mir MC, Li J, Klink JC et al (2014) Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol 66:204\u2013210","journal-title":"Eur Urol"},{"key":"3356_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0090-4295(02)02268-9","volume":"61","author":"SJ Freedland","year":"2003","unstructured":"Freedland SJ, Sutter ME, Dorey F et al (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61:365\u2013369","journal-title":"Urology"},{"key":"3356_CR26","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG et al (2022) The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 399:1886\u20131901","journal-title":"Lancet"},{"key":"3356_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijrobp.2007.02.035","volume":"69","author":"MT Spiotto","year":"2007","unstructured":"Spiotto MT, Hancock SL, King CR (2007) Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69:54\u201361","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.eururo.2017.10.009","volume":"74","author":"SJ Ramey","year":"2018","unstructured":"Ramey SJ, Agrawal S, Abramowitz MC et al (2018) Multi-institutional evaluation of elective nodal irradiation and\/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer. Eur Urol 74:99\u2013106","journal-title":"Eur Urol"},{"key":"3356_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215057","volume":"14","author":"C Song","year":"2019","unstructured":"Song C, Byun SJ, Kim YS et al (2019) Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis. PLoS ONE 14:e0215057","journal-title":"PLoS ONE"},{"key":"3356_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cncr.27712","volume":"119","author":"D Moghanaki","year":"2013","unstructured":"Moghanaki D, Koontz BF, Karlin JD et al (2013) Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Cancer 119:52\u201360","journal-title":"Cancer"},{"key":"3356_CR31","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","volume":"64","author":"ME Ray","year":"2006","unstructured":"Ray ME, Thames HD, Levy LB et al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64:1140\u20131150","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2490-14-33","volume":"14","author":"A Tomioka","year":"2014","unstructured":"Tomioka A, Tanaka N, Yoshikawa M et al (2014) Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 14:33","journal-title":"BMC Urol"},{"key":"3356_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00432-014-1612-8","volume":"140","author":"Y Kitagawa","year":"2014","unstructured":"Kitagawa Y, Ueno S, Izumi K et al (2014) Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP). Cancer Res Clin Oncol 140:673\u2013679","journal-title":"Cancer Res Clin Oncol"},{"key":"3356_CR34","first-page":"4605","volume":"29","author":"K Ogawa","year":"2009","unstructured":"Ogawa K, Nakamura K, Sasaki T et al (2009) Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months. Anticancer Res 29:4605\u20134613","journal-title":"Anticancer Res"},{"key":"3356_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/0284186X.2017.1364869","volume":"57","author":"D Bartkowiak","year":"2018","unstructured":"Bartkowiak D, Thamm R, Bottke D et al (2018) Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol 57:362\u2013367","journal-title":"Acta Oncol"},{"key":"3356_CR36","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.eururo.2016.07.028","volume":"71","author":"N Fossati","year":"2017","unstructured":"Fossati N, Karnes RJ, Boorjian SA et al (2017) Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol 71:886\u2013893","journal-title":"Eur Urol"},{"key":"3356_CR37","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591\u20131597","journal-title":"JAMA"},{"key":"3356_CR38","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ijrobp.2008.12.082","volume":"75","author":"AA Aizer","year":"2009","unstructured":"Aizer AA, Yu JB, McKeon AM et al (2009) Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 75:1344\u20131349","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0360-3016(96)00378-1","volume":"36","author":"CA Perez","year":"1996","unstructured":"Perez CA, Michalski J, Brown KC et al (1996) Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 36:573\u2013584","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","volume":"69","author":"CA Lawton","year":"2007","unstructured":"Lawton CA, DeSilvio M, Roach M III et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94\u201313 with emphasis on unexpected hormone\/radiation interactions. Int J Radiat Oncol Biol Phys 69:646\u2013655","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3356_CR41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijrobp.2006.05.074","volume":"66","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, DeSilvio M, Valicenti R et al (2006) Whole pelvis, \u201cmini-pelvis\u201d, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647\u2013653","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-023-03356-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:22:44Z","timestamp":1701487364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-023-03356-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3356"],"URL":"https:\/\/doi.org\/10.1007\/s11845-023-03356-z","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of The Jikei University School of Medicine [approval number 33\u2013251 (10869)], and informed consent was provided by opt-out. All procedures involving human participants in this study were conducted in accordance with the ethical standards of the institutional and\/or national research committees and the 1964 Declaration of Helsinki and its subsequent amendments or equivalent ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Takahiro Kimura is a paid consultant\/advisor to Astellas, Bayer, Janssen, and Sanofi. The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}